

**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION**  
**PHD CHAMBERS, 3RD FLOOR, 4/2, INSTITUTIONAL AREA, AUGUST KRANTI MARG, NEW DELHI-110049**  
 (A Private Company limited by guarantee under section 8 of the Companies Act 2013 )  
**BALANCE SHEET AS AT MARCH 31, 2021**

Particulars	Note No.	As at 31.03.2021 Rs.	As at 31.03.2020 Rs.
<b>EQUITY AND LIABILITIES</b>			
<b>Member's funds</b>			
Reserves and surplus	2	(116,584)	(53,830)
		<u>(116,584)</u>	<u>(53,830)</u>
<b>Current liabilities</b>			
Other current liabilities	3	179,000	195,288
<b>TOTAL</b>		<u><b>62,416</b></u>	<u><b>141,458</b></u>
<b>ASSETS</b>			
<b>Non-current assets</b>			
Fixed assets	4		
- Tangible assets		1,000	1,350
- Intangible assets		0	0
- Capital work in progress		0	0
		<u>1,000</u>	<u>1,350</u>
<b>Current assets</b>			
Cash and cash equivalents	5	54,446	132,505
Other Receivable	6	6,970	7,603
<b>TOTAL</b>		<u><b>62,416</b></u>	<u><b>141,458</b></u>


Accompanying notes 1 to 10 form part of the financial statements

For and on behalf of the board

In terms of our report attached  
 For Singh K.V. Gupta & Co  
 Chartered Accountants  
 Firm Registration No. 000133N

CA. Rakesh K. Agarwal  
 Partner  
 M.No. 085908  
 Place : New Delhi

Date : 24th Aug. 2021



Lalit Kant  
 Director  
 DIN:07242018

Shyam Sunder Agrawal  
 Director  
 DIN:7701481


**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION**  
PHD CHAMBERS, 3RD FLOOR, 4/2, INSTITUTIONAL AREA, AUGUST KRANTI MARG, NEW DELHI--110049  
(A Private Company limited by guarantee under section 8 of the Companies Act 2013 )


**STATEMENT OF INCOME AND EXPENDITURE FOR THE YEAR ENDED MARCH 31, 2021**

Particulars	Note No.	Year ended 31.03.2021 Rs.	Year ended 31.03.2020 Rs.
<b>REVENUE</b>			
Income from Operation	7	-	1,037,378
Other Income	8	1,995	13,306
<b>TOTAL REVENUE</b>		<b>1,995</b>	<b>1,050,684</b>
<b>EXPENSES</b>			
Programme/Project Expenses	9	-	913,492
Other Expenses	10	64,400	78,864
Depreciation	4	350	471
<b>TOTAL EXPENSES</b>		<b>64,750</b>	<b>992,827</b>
<b>Surplus(Deficit) for the year</b>		<b>(62,755)</b>	<b>57,857</b>

Accompanying notes 1 to 10 form part of the financial statements

In terms of our report attached  
For Singh K.V. Gupta & Co  
Chartered Accountants  
Firm Registration No. 000133N



  
CA. Rakesh K. Agarwal  
Partner  
M.No. 085908  
Place : New Delhi  
Date : 24th Aug. 2021

For and on behalf of the board

  
Lalit Kant  
Director  
DIN:07242018

  
Shyam Sunder Agrawal  
Director  
DIN:7701481


**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION**  
(A Private Company limited by guarantee under section 8 of the Companies Act 2013 )  
**CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2021**

Rupees in '000'

	YEAR ENDED 31-03-2021	YEAR ENDED 31-03-2020
<b>A CASH FLOW FROM OPERATING ACTIVITIES</b>		
SURPLUS/-DEFICIT BEFORE TAX AND EXTRAORDINARY ITEMS	-62.76	57.86
<b>ADJUSTMENT FOR</b>		
DEPRECIATION	0.35	0.47
DEPRECIATION RESERVE	-	-
FINANCE CHARGES	-	-
INTEREST ON BANK DEPOSIT/ LOANS & ADVANCE	-1.99	-13.31
PROVISION FOR INCOME TAX	-	-
DEFERRED TAX ASSETS	-	-
TAX ON DIVIDEND	-	-
CAPITAL CHANGES	-64.40	45.02
<b>ADJUSTMENT FOR</b>		
(INCREASE) / DECREASE IN SUNDRY DEBTORS	-	-
INCREASE) / DECREASE IN INVENTORIES	-	-
(INCREASE) / DECREASE IN CURRENT ASSETS	0.63	-7.60
(INCREASE) / DECREASE IN LOANS & ADVANCES	-	-
INCREASE / (DECREASE) IN CURRENT LIABILITIES	-16.28	71.99
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>-80.05</b>	<b>109.41</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES</b>		
ADDITION TO FIXED ASSETS	-	-
SALE OF FIXED ASSETS	-	-
ADDITION TO WORK IN PROGRESS	-	-
INTEREST ON BANK DEPOSITS / LOANS & ADVANCES	1.99	13.31
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>1.99</b>	<b>13.31</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES</b>		
SHARE CAPITAL	-	-
SHARE APPLICATION MONEY PENDING ALLOTMENT	-	-
INVESTMENTS	-	-
DIVIDEND AND TAX ON DIVIDEND PAID	-	-
INCOME TAX PAID	-	-
FINANCING CHARGES	-	-
<b>NET CASH GENERATED/USED FROM FINANCING ACTIVITIES</b>	<b>-</b>	<b>-</b>
<b>NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)</b>	<b>-78.06</b>	<b>122.72</b>
<b>CASH &amp; CASH EQUIVALENTS AS AT OPENING DATE</b>	<b>132.51</b>	<b>9.79</b>
	<b>54.45</b>	<b>132.51</b>
<b>CASH &amp; CASH EQUIVALENTS AS AT CLOSING DATE</b>	<b>54.45</b>	<b>132.51</b>

As per our report of even date attached  
For Singh K. V. Gupta & Co.  
Chartered Accountants  
FRN 000133N

For & on behalf of the Board



(CA Rakesh K Agarwal)  
Partner

Membership No. 085908

Place : New Delhi

Date: 24th Aug. 2021

  
Lalit Kant      Shyam Sunder Agrawal  
Director      Director  
DIN:07242018    DIN:07701481

**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION**  
**(A Private Company Limited by Guarantee under section 8 of the Companies Act, 2013)**  
**PHD Chambers, 3<sup>rd</sup> Floor, 4/2, Institutional Area, August Kranti Marg, New Delhi-110049**  
**Tel.:- 011-45501795**

**Note – 1: SIGNIFICANT ACCOUNTING POLICIES:**

**A: ACCOUNTING CONCEPT**

The accounts are prepared on historical cost convention on accrual basis and also on a going concern basis in accordance with Generally Accepted Accounting Principles and accounting standards applicable in India as applicable under section 133 of the Companies Act 2013 read with MCA General Circular No. 15/2013 dated 13<sup>th</sup> September 2013 and other relevant provision of the Indian Companies Act 2013 read with the Companies (Accounts) Rules. 2014 except where otherwise stated.

**B. USE OF ESTIMATES**

The preparation of financial statements in conformity with the generally accepted accounting practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting year. Actual results could differ from those estimates. Differences between the actual results and estimates are recognised in the year in which the results are known/ materialized. Any revision to accounting estimates is recognised prospectively in current and future periods.

Contingencies are recorded when it is probable that a liability will be incurred, and the amount can be reasonably estimated.

**C: FIXED ASSETS AND DEPRECIATION**

Fixed Assets are stated at their original cost including freight, duties, customs and other incidental expenses relating to acquisition, installation and construction. Depreciation has been provided on written down value method over the useful life of Assets as specified in Schedule-II to the Companies Act 2013

**D: REVENUE RECOGNITION**

- 1) Grants, donations and service charges are recognized in the financial statements only when the same are sanctioned by the concerned agencies and received by the Company.
- 2) Interest on saving banks is recognized whenever same is credited by bank in the account of the Company.



**E:** Grants made to projects carried out through partner agencies are accounted for on the basis of utilization certificate/statement submitted by the grantees.

**F: FOREIGN EXCHANGE TRANSACTIONS**

Transactions in foreign currencies are recorded at the rate at which credit/ debit is given by the bank at the time of occurrence of the transaction.

**G: PROVISIONS**

A provision is recognized when an enterprise has a present obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

**H: OTHERS**

Accounting Policies not specifically referred to otherwise are consistent with generally accepted accounting principles followed by the Company.



**NOTES TO THE ACCOUNTS:**

**A:** This is the Fourth Year of the Company as the Company was incorporated on 27<sup>th</sup> May 2016 as a private company limited by guarantee and not having a share capital and was granted a license no. 107097 dated 23<sup>rd</sup> May 2016 under section 8(1) of the Companies Act, 2013, by Government of India- Ministry of Corporate Affairs. The Company has been granted registration under section 12AA of the Income Tax Act 1961 vide letter no CIT (E)/DEL-DR26044-23032017/7387 dated 23<sup>rd</sup> March 2017 & approval under section 80-G of the Income Tax Act 1961 vide letter no. CIT(E)/DEL-DE27667-23032017/8506 dated 23<sup>rd</sup> March 2017 by Commission of Income Tax (Exemption) Delhi

**B: Foreign Exchange Earning & Out – Go.**

Particulars	Current Year	Previous Year
Earning	0.00	0.00
Out – Go (Foreign Travel Exp.)	0.00	2,03,369.77

**C: Related Party Transactions**

In the normal course of business, the Company enters into transactions with key management personnel. The names of related parties of the Company and their relationship, as required to be disclosed under Accounting Standard 18 are as follows:

**a) Related party and nature of related party relationship with whom transaction have taken place during the year**

Relationship	Name of the related party
Key Management Personnel	Dr Lalit Kant-Director
Key Management Personnel	Dr. Shyam Sundar-Director

**b) Summary of Significant transaction and outstanding balances with related parties (Figures in lakhs)**

Name of the related party	Nature of Transaction	Current year	Previous year	Outstanding as on 31 <sup>st</sup> Mar 21	Outstanding as on 31 <sup>st</sup> Mar 20
DR Shyam Sundar	Reimbursement of Travelling Expenses	0.00	4,000	0	0

**D:** Amount due from Director Rs.NIL

**E:** Provision for taxation has not been made in accounts in the absence of any income.

**F:** The Company is a Small and Medium Sized Company (SMC) as defined in the General



Instructions in respect of Accounting Standards notified under the Companies Act, 1956. Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company.



**G:** Notes A to G form an integral part of the balance sheet and income & expenditure account.

***For and on behalf of the Board of Directors  
Of DNDI Drugs for Neglected Diseases Initiative India Foundation***

  
**Lalit Kant**  
**Director**  
**DIN:07242018**

  
**Shyam Sunder Agrawal**  
**Director**  
**DIN:07701481**

**Date:** 24<sup>th</sup> Aug. 2021  
**Place:** New Delhi


**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION**  
(A Private Company limited by guarantee under section 8 of the Companies Act 2013 )

**2 Reserves and surplus**

	As at 31.03.2021	As at 31.03.2020
	Rs.	
<b>(a) Surplus in Statement of Income &amp; Expenditure Account</b>		
Opening balance	(53,830)	(1,11,687)
Add: Excess of income over expenditure	(62,755)	57,857
Closing balance	<u>(1,16,584)</u>	<u>(53,830)</u>

**3 Other current liabilities**

	As at 31.03.2021	As at 31.03.2020
	Rs.	Rs.
Payable to related party	-	-
Audit Fees Payable	1,75,250	1,77,300
Other Expenses Payable	0	5,400
TDS payable	3,750	12,588
	<u>1,79,000</u>	<u>1,95,288</u>





**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION**  
(A Private Company limited by guarantee under section 8 of the Companies Act 2013 )

Notes to the accounts (continued)

**4 Fixed Assets**

(Amount in INR)

Particulars	GROSS BLOCK		DEPRECIATION				Net block	
	As at 01.04.2020	As at 31.03.2021	As at 01.04.2020	For the year	On deductions	As at 31.03.2021	As at 31.03.2020	
<b>Tangible Assets</b>								
Furniture & Fixture	3375	3375	2025	350	0	2375	1350	
<b>Total Tangible Assets</b>	<b>3375</b>	<b>3375</b>	<b>2025</b>	<b>350</b>	<b>0</b>	<b>2375</b>	<b>1350</b>	
Intangible Assets	0	0	0	0	0	0	0	
Capital - work - in progress	0	0	0	0	0	0	0	
<b>Previous Year's Figures</b>	<b>3375</b>	<b>3375</b>	<b>1554</b>	<b>471</b>	<b>0</b>	<b>2025</b>	<b>1821</b>	



**DNDI DRUGS FOR NEGLECTED DISEASES INITIATIVE INDIA FOUNDATION**  
(A Private Company limited by guarantee under section 8 of the Companies Act 2013 )

Notes to the accounts (continued)

**5 Cash and cash equivalents**

	As at 31.03.2021 Rs.	As at 31.03.2020 Rs.
Balances with banks		
- Saving accounts	54,446	1,17,692
Cash in hand	0	14,813
	<b>54,446</b>	<b>1,32,505</b>

**6 Other Receivable**

	As at 31.03.2021 Rs.	As at 31.03.2020 Rs.
TDS recoverable from Hotel Holiday Inn	6,637	6,637
Interest Receivable	333	966
	<b>6,970</b>	<b>7,603</b>

**7 Revenue from Operations**

	As at 31.03.2021 Rs.	As at 31.03.2020 Rs.
Service Charges	-	10,37,378
	-	<b>10,37,378</b>

**8 Other Income**


	As at 31.03.2021 Rs.	As at 31.03.2020 Rs.
Saving Bank Interest	1,995	13,306
	<b>1,995</b>	<b>13,306</b>

**9 Programme/Project Expenses**

	As at 31.03.2021 Rs.	As at 31.03.2020 Rs.
Meeting Expenses	0	1,09,268
Travelling Expenses	0	4,54,855
Dinner Expenses	0	60,800
Lodging & Boarding Expenses	0	2,44,239
Consultancy Fees	0	30,000
Local Conveyance Expenses	0	10,005
Recruitment Expenses	0	4,130
Printing & Stationery Expenses	0	195
	<b>0</b>	<b>9,13,492</b>

**10 Other expenses**

	As at 31.03.2021 Rs.	As at 31.03.2020 Rs.
Bank Charges	0	13,513
Legal & Professional Charges	5,000	0
Filing Fees	400	0
Auditors' remuneration		
- As auditors	50,000	50,000
- for certification	0	5,000
-GST on above	9,000	9,900
Interest on TDS	0	451
	<b>64,400</b>	<b>78,864</b>





SINGH K. V. GUPTA & CO  
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITORS' REPORT

To

The Members

**DNDI Drugs for Neglected Diseases Initiative India Foundation**

**New Delhi**

**Report on the audit of the financial statements**

**Opinion**

We have audited the accompanying financial statements of **DNDI Drugs for Neglected Diseases Initiative India Foundation** ("the Company"), which comprise the balance sheet as at March 31, 2021, and the Statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, its deficit and cash flows for the year ended on that date.

**Basis for opinion**

We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



### **Key audit matters**


Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

### **Information other than the financial statements and auditors' report thereon**

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexure to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

### **Management's responsibility for the financial statements**


The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable



and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The board of directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management. Conclude on the appropriateness of management's use of the going concern basis of accounting and



based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on other legal and regulatory requirements**

- 1) The provisions of the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 is not applicable to the Company as the Company is to licensed operate u/s 8 of the Companies Act 2013.


As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;



- (c) The balance sheet, the statement of profit and loss, and the cash flow statement dealt with by this report are in agreement with the books of account;
- (d) In our opinion, the aforesaid financial statements comply with the accounting standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;
- (e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the board of directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;
- The Company does not have any pending litigations which would impact its financial position;
  - The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
  - There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company

For Singh K V Gupta & Co  
Chartered Accountants  
Firm Registration No.000133N

  
CA. Rakesh Agarwal  
Partner

Membership No.0859087  
UDIN : 21085908AAAA DZ 9000  
Place: New Delhi  
Date:24<sup>th</sup> Aug.2021



## **Annexure "A" to the Independent Auditor's Report**

(Referred to in paragraph 2 (f) under 'Report on other legal and regulatory requirements' section of our report to the Members of **DNDI Drugs for Neglected Diseases Initiative India Foundation** of even date)

**Report on the internal financial controls over financial reporting under clause (i) of sub – section 3 of section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of **DNDI Drugs for Neglected Diseases Initiative India Foundation** ("the Company") as at March 31, 2021, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

### **Management's responsibility for internal financial controls**

The board of directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

### **Auditors' responsibility**

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the standards on auditing prescribed under Section 143 (10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those standards and the guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls





operated effectively in all material respects. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement in the financial statements, whether due to fraud or error. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial control system over financial reporting.

#### **Meaning of internal financial controls over financial reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

#### **Limitations of internal financial controls over financial reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management of override of controls, material misstatements due to error or fraud may occur and not be detected. Also projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.




## Opinion

In our opinion and according to the information and explanations given to us, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Singh K V Gupta & Co  
Chartered Accountants  
Firm Registration No 000133N



  
CA Rakesh Agarwal  
Partner  
Membership No. 085908  
UDIN : 21085908AAAA029000  
Place: New Delhi  
Date: 24<sup>th</sup> Aug.2021

**DNDi Drugs for Neglected Diseases initiative**  
**India Foundation**

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

**DIRECTORS' REPORT**

**Dear Members**

Your directors have the pleasure to present the Fifth report of the directors (the "Report") of your Company together with the Audited Annual Accounts for the financial year ended 31<sup>st</sup> March 2021.

**Financial Highlights**

Particulars	(Figures in Rs.)	
	Financial Year ended on March 31, 2021	Financial Year ended on March 31, 2020
Total Income	1,995	10,50,684
Total Expenditure	64,750	9,92,827
Surplus (Deficit) for the year	(62,755)	57,857
Less: Current tax	0.00	0.00
Surplus (Deficit) after tax	(62,755)	57,857
Add: Balance as per last Balance Sheet	(53,830)	(1,11,687)
Balance Transferred to Balance Sheet	(1,16,585)	(53,830)

**State of Company's Affairs**

DNDI Drugs for Neglected Diseases Initiative India Foundation ('the Company'), a not for profit company, within the meaning of section 8 of the Companies Act 2013. The prime focus of the Company is to provide support and to stimulate research and development, primarily of drugs, as well as vaccines and diagnostics for patients suffering from neglected diseases.

During the year, no activity was carried out by the Company. Your Company is in process of filing an application for prior permission under FCRA for receiving foreign grant/donation.

Once FCRA permissions is in place, Your Directors are optimistic about company's operations and hopeful of better performance with increased grants/donations in coming year/s.

**Material changes and commitment, if any, affecting the financial position of the Company**

Save as mentioned elsewhere in this Report, no material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year of the Company and the date of this Report.

**Public Deposits**

During the year under review, your Company did not accept any deposits in terms of the provisions of section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014.

**Number of meetings of the Board held during the financial year and attendance by Directors**

During the year under review, three Board meetings were held on June 19<sup>th</sup>, 2020, December 17<sup>th</sup>, 2020, and March 3<sup>rd</sup>, 2021. The details of the Board meetings attended during the financial year by the Directors of the Company are as follows:

Date of the Board meeting	Lalit Kant	Shyam Sundar Agrawal
June 19 <sup>th</sup> , 2020	Yes	Yes
December 17 <sup>th</sup> , 2020	Yes	Yes
March 3 <sup>rd</sup> , 2021	Yes	Yes

**DNDi Drugs for Neglected Diseases *initiative***  
**India Foundation**

(CIN: U73100DI.2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

---

**Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo**

- A. Conservation of energy:** Since the Company is not engaged in any manufacturing activity, issues relating to conservation of energy and technology absorption are not quite relevant to its functioning.
- B. Technology absorption:** Since the Company is not engaged in any manufacturing activity, issues relating to conservation of energy and technology absorption are not quite relevant to its functioning.
- C. Foreign exchange earnings and Outgo:**

Earnings in foreign exchange (actual inflows):	Nil
Expenditure in foreign currency (actual outflows):	Nil

**Transfer to reserves**

No amount was transferred to the reserves during the financial year ended 31<sup>st</sup> March 2021.

**Particulars of contracts or arrangements made with related parties**

The Company did not enter into any contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013.

**Particulars of loans, guarantees or investments made under section 186 of the Companies Act, 2013**

The Company did not provide any loan, guarantee or investment pursuant to section 186 of the Companies Act, 2013.

**Directors and Key Managerial Personnel**

There has been no change in the composition of the directors of the Company during the year under review. Dr. Lalit Kant and Dr. Shyam Sundar Agrawal were the directors of the Company during the year 2020-21.

**Statement of particulars of employees pursuant to provisions of rule 5(2) & (3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014**

The Company had no employees during the year under review.

**Directors' Responsibility Statement**

In terms of the provisions of section 134 (5) of the Companies Act, 2013, and to the best of their knowledge and belief and according to the information and explanations obtained by them and save as mentioned elsewhere in this Report, the attached Annual Accounts and the Auditors' Report thereon, your Directors confirm that:

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss for that period;
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the directors had prepared the annual accounts on a going concern basis; and
- (e) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

**DNDi Drugs for Neglected Diseases *initiative***  
**India Foundation**

(CIN: U73100DL2016NPL300545)

Registered Office: PHD Chamber, 3rd Floor, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi 110016, India

Ph: +91-11-45501795; E-mail: dndiindiafoundation@gmail.com

---

**Auditors**

M/s. Singh K.V. Gupta & Co., Chartered Accountants, Statutory Auditors of the Company, to hold office until the conclusion of the sixth Annual General Meeting.

**Auditors' Report**

The Auditor's Report for the period has been annexed with this report and the comments made by the Statutory Auditors in the Auditor's Report are self-explanatory.

**Statement concerning development and implementation of risk management policy of the Company**

In the opinion of the Board of Directors of the Company, no risks which may threaten the existence of the Company have been identified and therefore no risk management policy has been framed.

**Subsidiaries, joint ventures and associate Companies**

The Company does not have any Subsidiary, Joint Venture or Associate Company.

**Details of significant & material orders passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future**

No significant & material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

**Adequacy of internal financial controls**

The Company has in place adequate internal financial controls with reference to financial statements. During the year under review, such controls were tested and no reportable material weakness in the design or operation were observed.

**Maintenance of cost records**

The Company is not required to maintain cost records as specified by the Central Government under section 148(1) of the Companies Act, 2013.

**Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013**

The Company is not required to constitute Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

**Acknowledgment**

Your Directors take this opportunity to place on record their sincere appreciation for the co-operation and assistance the Company has received from banks and various Government Departments.

For and on behalf of the Board of Directors of  
**DNDi Drugs for Neglected Diseases Initiative India Foundation**

  
\_\_\_\_\_  
(Lalit Kant)

Director

DIN: 07242018

Address: B-95, Block B, Gulmohar Park,  
New Delhi – 110049, India

Date: August 24<sup>th</sup>, 2021

Place: New Delhi

  
\_\_\_\_\_  
(Shyam Sunder Agrawal)

Director

DIN: 07701481

Address: 6, S K Gupta Nagar, Lanka  
Varanasi -221005 (UP)

Date: August 24<sup>th</sup>, 2021

Place: Varanasi